<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03884426</url>
  </required_header>
  <id_info>
    <org_study_id>RC12_0143</org_study_id>
    <nct_id>NCT03884426</nct_id>
  </id_info>
  <brief_title>Genetic and Phenotypic Characteristics of Mitral Valve Prolapse</brief_title>
  <acronym>MVP</acronym>
  <official_title>Genetic and Phenotypic Characteristics of Mitral Valve Prolapse</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Brest</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phenotypic characterisation of MVP by echocardiography in families. Identification of genes
      involved in MVP.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After clinical identification of patients with MVP, doctors organize 1st degree relative
      familial screening. A comprehensive echocardiography was carried out along with clinical
      examination. All echo data were stored for off-line analysis by a sonographer in our
      Core-lab. Blood was sample at the time of echocardiography in adult patients for DNA
      analyses. Follow-up for mitral valve changes will be performed after 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Family-Based</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>MVP defined by a superior displacement of at least 2 mm</measure>
    <time_frame>At Day 0</time_frame>
    <description>MVP defined by a superior displacement of at least 2 mm</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comprehensive mitral valve apparatus characterization per size of items (leaflets, chordae, annulus)</measure>
    <time_frame>At Day 0</time_frame>
    <description>Leaflets length ; Chordae length ; Annulus diameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comprehensive mitral valve apparatus characterization per other items (papillary muscle, ventricles)</measure>
    <time_frame>At Day 0</time_frame>
    <description>Papillary muscles aspect ; Right Ventricle function ; Left Ventricle Ejection Fraction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comprehensive mitral valve apparatus characterization per size of items (ventricle and atrium sizes)</measure>
    <time_frame>At Day 0</time_frame>
    <description>Left ventricle and atrium sizes ; right ventricle size ; right Atrium size</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comprehensive mitral valve apparatus characterization per size of items</measure>
    <time_frame>At Day 0</time_frame>
    <description>Leaflets thickness</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of cardiac or clinical defects associated with MVP</measure>
    <time_frame>At Day 0 Follow-up will be carried out at 5 and 10 years</time_frame>
    <description>Atrial septal defect, ventricular septal defect, patent ductus arteriosus, tricuspid or aortic valve abnormalities (prolapse, bicuspid AV…), coarctation, ascending aorta aneurysm</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Mitral Valve Prolapse</condition>
  <condition>Genetic Disease</condition>
  <arm_group>
    <arm_group_label>Patients with MVP</arm_group_label>
    <description>The patients concerned are patients with known or recently discovered Barlow-type mitral prolapse, whatever the degree of severity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal relatives</arm_group_label>
    <description>Related healthy patients, for an average of 6 individuals per family</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients of both sex of any age with typical mitral valve prolapse and relatives examined
        during familial screening
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients of any age

          -  with typical mitral valve prolapse

          -  relatives examined during familial screening

        Exclusion Criteria:

          -  Refusal of the patient
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vincent Probst, PU-PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nantes University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hervé Le Marec, PU-PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nantes University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-Jacques Schott, DR</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut National de la Santé Et de la Recherche Médicale, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thierry Le Tourneau, PU-PH</last_name>
    <phone>0617908670</phone>
    <email>thletourneau@yahoo.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Brest University Hospital</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jacques Mansourati, PU-PH</last_name>
      <phone>02 98 34 73 91</phone>
      <email>jacques.mansourati@chu-brest.fr</email>
    </contact>
    <investigator>
      <last_name>Yves Etienne, PH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yannick Jobic, PH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nantes University Hospital</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry Le Tourneau, PU-PH</last_name>
      <phone>0617908670</phone>
      <email>thletourneau@yahoo.fr</email>
    </contact>
    <investigator>
      <last_name>Thierry Le Tourneau, PU-PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rennes University Hospital</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erwan Donal, PU-PH</last_name>
      <phone>02 99 28 25 27</phone>
      <email>erwan.donal@chu-rennes.fr</email>
    </contact>
    <investigator>
      <last_name>Erwan Donal, PU-PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 21, 2013</study_first_submitted>
  <study_first_submitted_qc>March 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 21, 2019</study_first_posted>
  <last_update_submitted>March 19, 2019</last_update_submitted>
  <last_update_submitted_qc>March 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mitral valve prolapse</keyword>
  <keyword>genetic</keyword>
  <keyword>echocardiography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitral Valve Prolapse</mesh_term>
    <mesh_term>Genetic Diseases, Inborn</mesh_term>
    <mesh_term>Prolapse</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

